IVIXF (Invion) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


IVIXF Invion Ltd IVIXF
16 GF Score
Price $0.04
GF Value $0.17
! 2 Warning Signs
View Full Analysis

What is Invion Tariff Resilience Score?

Invion IVIXF -83.23% 16 Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.17. The stock has 2 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Invion ranks better than 97.09% on this metric.

Invion has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Invion has Invion Ltd operates primarily in the biotech sector, which is less affected by tariffs. Its supply chain is not heavily reliant on international trade, and it has some pricing power in niche markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Invion might have Highly Resilient.

Invion  (OTCPK:IVIXF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Invion Tariff Resilience Score Related Terms

IVIXF vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invion Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Invion's Tariff Resilience Score falls into.


IVIXF
16GF Score
Invion Ltd IVIXF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Invion (IVIXF) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Invion ranks #30 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Invion's Tariff Resilience Score too high?
Invion's current Tariff Resilience Score is 7. Based on the distribution chart, Invion ranks #30 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #30 out of 1031 companies for Tariff Resilience Score. This places Invion in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Invion's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current Tariff Resilience Score of 7. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current Tariff Resilience Score is 7. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Invion (IVIXF), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

  • Tariff Resilience Score: 7
  • GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
  • GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Other Exchanges 7C8:GermanyIVX:Australia
Address 692 High Street, East Kew, VIC, AUS, 3102
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score

Get the complete analysis for IVIXF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.17
GF Value